Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

The primary objectives of the study are: * To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities, and their change over-time. * To characterize patients who receive DUPIXENT® for CRSwNP in a real-world setting with respect to their medical history, demographic and disease characteristics, and type 2 comorbidities The secondary objectives of the study are: * To characterize real-world utilization of DUPIXENT® for patients with CRSwNP * To collect patient and physician global assessment of disease severity and treatment satisfaction for patients receiving DUPIXENT® for CRSwNP * To collect long-term safety data for patients receiving DUPIXENT® for CRSwNP

Key Inclusion Criteria: * All patients who are newly initiated on DUPIXENT® for the treatment of CRSwNP according to the respective prescribing information (Product Label or SmPC) * Willing and able to comply with clinic visits and study-related procedures as per protocol * Provide informed consent signed by study patient or legally acceptable representative * Able to understand and complete study-related questionnaires as per protocol Key Exclusion Criteria: * Patients who have a contraindication to DUPIXENT® according to the country-specific prescribing information * Any previous treatment with DUPIXENT® for any condition * Any condition that, in the opinion of the investigator, may interfere with the patient's ability to participate in the study per protocol * Participation in an ongoing interventional or observational study that might, in the treating physician's opinion, influence the assessments for the current study per protocol